JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More
Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More
J.B.CHEMICALS | FULFORD INDIA | J.B.CHEMICALS/ FULFORD INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 35.6 | 398.8 | 8.9% | View Chart |
P/BV | x | 6.6 | 6.2 | 106.6% | View Chart |
Dividend Yield | % | 0.2 | 0.1 | 209.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
J.B.CHEMICALS Mar-18 |
FULFORD INDIA Mar-14 |
J.B.CHEMICALS/ FULFORD INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 363 | 942 | 38.5% | |
Low | Rs | 255 | 450 | 56.7% | |
Sales per share (Unadj.) | Rs | 169.1 | 691.4 | 24.5% | |
Earnings per share (Unadj.) | Rs | 16.6 | 11.5 | 144.8% | |
Cash flow per share (Unadj.) | Rs | 23.4 | 15.4 | 152.5% | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 100.0% | |
Dividend yield (eoy) | % | 0.6 | 0.3 | 225.2% | |
Book value per share (Unadj.) | Rs | 172.5 | 380.0 | 45.4% | |
Shares outstanding (eoy) | m | 83.57 | 3.90 | 2,142.8% | |
Bonus/Rights/Conversions | BB | - | - | ||
Price / Sales ratio | x | 1.8 | 1.0 | 181.5% | |
Avg P/E ratio | x | 18.6 | 60.7 | 30.7% | |
P/CF ratio (eoy) | x | 13.2 | 45.3 | 29.1% | |
Price / Book Value ratio | x | 1.8 | 1.8 | 97.8% | |
Dividend payout | % | 12.0 | 17.4 | 69.0% | |
Avg Mkt Cap | Rs m | 25,827 | 2,714 | 951.5% | |
No. of employees | `000 | 3.8 | 0.4 | 849.5% | |
Total wages/salary | Rs m | 2,511 | 505 | 497.2% | |
Avg. sales/employee | Rs Th | 3,747.4 | 6,073.0 | 61.7% | |
Avg. wages/employee | Rs Th | 665.7 | 1,137.4 | 58.5% | |
Avg. net profit/employee | Rs Th | 367.8 | 100.7 | 365.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 14,135 | 2,696 | 524.2% | |
Other income | Rs m | 366 | 125 | 291.7% | |
Total revenues | Rs m | 14,501 | 2,822 | 513.9% | |
Gross profit | Rs m | 2,178 | -46 | -4,694.6% | |
Depreciation | Rs m | 570 | 15 | 3,748.0% | |
Interest | Rs m | 35 | 10 | 367.4% | |
Profit before tax | Rs m | 1,940 | 54 | 3,571.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 552 | 10 | 5,753.1% | |
Profit after tax | Rs m | 1,387 | 45 | 3,103.4% | |
Gross profit margin | % | 15.4 | -1.7 | -895.5% | |
Effective tax rate | % | 28.5 | 17.7 | 161.1% | |
Net profit margin | % | 9.8 | 1.7 | 592.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 10,470 | 1,738 | 602.3% | |
Current liabilities | Rs m | 2,749 | 545 | 504.7% | |
Net working cap to sales | % | 54.6 | 44.3 | 123.4% | |
Current ratio | x | 3.8 | 3.2 | 119.3% | |
Inventory Days | Days | 55 | 48 | 113.9% | |
Debtors Days | Days | 78 | 4 | 1,804.0% | |
Net fixed assets | Rs m | 5,811 | 12 | 48,833.0% | |
Share capital | Rs m | 167 | 39 | 428.5% | |
"Free" reserves | Rs m | 14,248 | 1,443 | 987.4% | |
Net worth | Rs m | 14,416 | 1,482 | 972.7% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 17,649 | 2,077 | 849.9% | |
Interest coverage | x | 56.6 | 6.7 | 842.4% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.8 | 1.3 | 61.7% | |
Return on assets | % | 8.1 | 2.6 | 308.7% | |
Return on equity | % | 9.6 | 3.0 | 319.0% | |
Return on capital | % | 13.7 | 4.3 | 318.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 24.5 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 659 | 0.0% | |
Fx inflow | Rs m | 6,164 | 17 | 35,836.6% | |
Fx outflow | Rs m | 1,334 | 673 | 198.2% | |
Net fx | Rs m | 4,829 | -656 | -736.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,231 | 90 | 1,367.2% | |
From Investments | Rs m | -208 | 105 | -198.9% | |
From Financial Activity | Rs m | -595 | -14 | 4,221.3% | |
Net Cashflow | Rs m | 427 | 181 | 236.6% |
Indian Promoters | % | 55.4 | 0.0 | - | |
Foreign collaborators | % | 0.3 | 75.0 | 0.4% | |
Indian inst/Mut Fund | % | 3.4 | 3.8 | 89.2% | |
FIIs | % | 3.9 | 0.1 | 3,900.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 37.0 | 21.2 | 174.5% | |
Shareholders | 30,437 | 4,783 | 636.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare J.B.CHEMICALS With: STERLING BIOTECH PFIZER ALKEM LABORATORIES ORCHID PHARMA SANOFI INDIA
Compare J.B.CHEMICALS With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge buying interest during the extended closing hours yesterday and ended on a strong note.
For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.
For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.
Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.
For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.
For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.
More Views on NewsIn this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More